Veracyte Quarterly Income Statements Chart
Quarterly
|
Annual
Veracyte Quarterly Income Statements Table
Quarterly
|
Annual
| Unit: USD | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 | 2022-09-30 | 2022-06-30 | 2022-03-31 | 2021-12-31 | 2021-09-30 | 2021-06-30 | 2021-03-31 | 2020-12-31 | 2020-09-30 | 2020-06-30 | 2020-03-31 | 2019-12-31 | 2019-09-30 | 2019-06-30 | 2019-03-31 | 2018-12-31 | 2018-09-30 | 2018-06-30 | 2018-03-31 | 2017-12-31 | 2017-09-30 | 2017-06-30 | 2017-03-31 | 2016-12-31 | 2016-09-30 | 2016-06-30 | 2016-03-31 | 2015-09-30 | 2015-06-30 | 2015-03-31 | 2014-06-30 | 2014-03-31 | 2013-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| revenue: | ||||||||||||||||||||||||||||||||||||||||||||
| testing revenue | 122,263,000 | 107,309,000 | 112,152,000 | 109,536,000 | 106,970,000 | 90,303,000 | 90,385,000 | 82,012,000 | 81,749,000 | 72,396,000 | 70,269,000 | 64,577,000 | 59,718,000 | 55,980,000 | 53,414,000 | 50,897,000 | 50,793,000 | 33,078,000 | 31,497,000 | 28,270,000 | 15,212,000 | 26,991,000 | ||||||||||||||||||||||
| product revenue | 3,598,000 | 3,580,000 | 3,019,000 | 3,188,000 | 3,906,000 | 3,537,000 | 3,665,000 | 4,020,000 | 4,011,000 | 3,892,000 | 3,231,000 | 3,314,000 | 3,108,000 | 2,979,000 | 2,758,000 | 2,959,000 | 2,688,000 | 3,059,000 | 2,696,000 | 2,027,000 | 1,713,000 | 3,409,000 | ||||||||||||||||||||||
| biopharmaceutical and other revenue | 4,303,000 | 3,584,000 | 3,461,000 | 3,136,000 | 3,552,000 | 3,004,000 | 4,149,000 | 4,076,000 | 4,562,000 | 6,134,000 | 6,797,000 | 7,701,000 | 10,038,000 | 8,824,000 | 11,164,000 | 6,514,000 | ||||||||||||||||||||||||||||
| total revenue | 130,164,000 | 114,473,000 | 118,632,000 | 115,860,000 | 114,428,000 | 96,844,000 | 98,199,000 | 90,108,000 | 90,322,000 | 82,422,000 | 80,297,000 | 75,592,000 | 72,864,000 | 67,783,000 | 67,336,000 | 60,370,000 | 55,105,000 | 36,703,000 | 34,536,000 | 31,121,000 | 20,704,000 | 31,122,000 | ||||||||||||||||||||||
| yoy | 13.75% | 18.20% | 20.81% | 28.58% | 26.69% | 17.50% | 22.29% | 19.20% | 23.96% | 21.60% | 19.25% | 25.21% | 32.23% | 84.68% | 94.97% | 93.98% | 166.16% | 17.93% | ||||||||||||||||||||||||||
| qoq | 13.71% | -3.51% | 2.39% | 1.25% | 18.16% | -1.38% | 8.98% | -0.24% | 9.58% | 2.65% | 6.22% | 3.74% | 7.50% | 0.66% | 11.54% | 9.55% | 50.14% | 6.27% | 10.97% | 50.31% | -33.47% | |||||||||||||||||||||||
| cost of revenue: | ||||||||||||||||||||||||||||||||||||||||||||
| cost of testing revenue | 32,407,000 | 28,260,000 | 31,645,000 | 29,029,000 | 27,920,000 | 25,979,000 | 24,105,000 | 21,827,000 | 23,333,000 | 19,648,000 | 19,394,000 | 19,816,000 | 18,584,000 | 17,523,000 | 16,366,000 | 16,073,000 | 15,589,000 | 10,832,000 | 9,756,000 | 9,118,000 | 6,471,000 | 10,568,000 | ||||||||||||||||||||||
| cost of product revenue | 1,749,000 | 1,422,000 | 2,800,000 | 1,792,000 | 1,874,000 | 2,644,000 | 1,753,000 | 2,436,000 | 2,315,000 | 2,162,000 | 2,618,000 | 1,981,000 | 1,646,000 | 1,575,000 | 1,583,000 | 1,491,000 | 1,323,000 | 1,490,000 | 1,382,000 | 1,048,000 | 932,000 | 1,559,000 | ||||||||||||||||||||||
| cost of biopharmaceutical and other revenue | 3,572,000 | 2,698,000 | 2,622,000 | 3,112,000 | 3,812,000 | 2,838,000 | 3,518,000 | 3,347,000 | 4,040,000 | 4,419,000 | 4,819,000 | 4,211,000 | 4,800,000 | 4,615,000 | 4,933,000 | 4,079,000 | ||||||||||||||||||||||||||||
| intangible asset amortization - cost of revenue | 2,667,000 | 2,585,000 | 2,811,000 | 2,917,000 | 2,909,000 | |||||||||||||||||||||||||||||||||||||||
| total cost of revenue | 40,395,000 | 34,965,000 | 39,878,000 | 36,850,000 | 36,515,000 | |||||||||||||||||||||||||||||||||||||||
| gross profit | 89,769,000 | 79,508,000 | 78,754,000 | 79,010,000 | 77,913,000 | |||||||||||||||||||||||||||||||||||||||
| yoy | 15.22% | |||||||||||||||||||||||||||||||||||||||||||
| qoq | 12.91% | 0.96% | -0.32% | 1.41% | ||||||||||||||||||||||||||||||||||||||||
| gross margin % | 68.97% | 69.46% | 66.39% | 68.19% | 68.09% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | ||||||||||||||||||||||
| operating expenses: | ||||||||||||||||||||||||||||||||||||||||||||
| research and development | 16,264,000 | 17,720,000 | 19,290,000 | 17,574,000 | 16,465,000 | 15,965,000 | 18,673,000 | 13,322,000 | 12,541,000 | 12,769,000 | 11,287,000 | 10,773,000 | 9,377,000 | 9,166,000 | 10,252,000 | 8,006,000 | 6,249,000 | 5,336,000 | 4,586,000 | 4,042,000 | 4,169,000 | 4,407,000 | 4,443,000 | 3,643,000 | 3,330,000 | 3,435,000 | 3,125,000 | 3,419,000 | 4,601,000 | 3,675,000 | 3,202,000 | 3,046,000 | 3,603,000 | 4,030,000 | 3,590,000 | 4,006,000 | 4,267,000 | 3,461,000 | 3,563,000 | 3,103,000 | 2,787,000 | 2,243,000 | 2,126,000 | 2,028,000 |
| selling and marketing | 25,316,000 | 24,454,000 | 24,824,000 | 22,612,000 | 24,216,000 | 23,782,000 | 25,260,000 | 24,344,000 | 25,756,000 | 26,130,000 | 24,127,000 | 25,678,000 | 24,001,000 | 23,754,000 | 22,212,000 | 21,670,000 | 19,662,000 | 16,296,000 | 13,149,000 | 10,955,000 | 10,701,000 | 17,584,000 | 14,183,000 | 13,088,000 | 13,943,000 | 12,477,000 | 10,066,000 | 10,081,000 | 9,623,000 | 11,543,000 | 9,045,000 | 7,885,000 | 7,994,000 | 7,336,000 | 5,832,000 | 7,087,000 | 8,263,000 | 7,066,000 | 6,048,000 | 6,937,000 | 5,620,000 | 5,101,000 | 4,336,000 | 3,291,000 |
| general and administrative | 32,331,000 | 33,808,000 | 26,913,000 | 25,742,000 | 31,745,000 | 26,210,000 | 23,795,000 | 16,334,000 | 25,047,000 | 22,463,000 | 18,208,000 | 17,600,000 | 19,798,000 | 20,912,000 | 18,849,000 | 20,749,000 | 15,473,000 | 46,282,000 | 12,413,000 | 8,546,000 | 7,957,000 | 7,813,000 | 8,581,000 | 6,624,000 | 6,920,000 | 6,904,000 | 6,645,000 | 5,742,000 | 5,932,000 | 5,644,000 | 5,357,000 | 5,520,000 | 6,192,000 | 6,019,000 | 5,725,000 | 5,763,000 | 6,071,000 | 6,228,000 | 5,728,000 | 5,536,000 | 5,798,000 | 3,928,000 | 3,982,000 | 3,244,000 |
| impairment of assets | 20,505,000 | |||||||||||||||||||||||||||||||||||||||||||
| intangible asset amortization - operating expenses | 621,000 | 622,000 | 798,000 | 880,000 | 881,000 | |||||||||||||||||||||||||||||||||||||||
| total operating expenses | 95,037,000 | 76,604,000 | 74,579,000 | 66,993,000 | 73,307,000 | 101,500,000 | 133,706,000 | 121,847,000 | 98,373,000 | 92,920,000 | 85,717,000 | 85,272,000 | 83,597,000 | 83,031,000 | 79,669,000 | 77,051,000 | 62,579,000 | 82,118,000 | 42,608,000 | 35,187,000 | 31,755,000 | 43,322,000 | 37,927,000 | 32,736,000 | 33,236,000 | 31,596,000 | 28,807,000 | 27,770,000 | 28,668,000 | 28,996,000 | 25,640,000 | 23,887,000 | 25,015,000 | 23,949,000 | 21,929,000 | 23,489,000 | 25,169,000 | 23,301,000 | 21,223,000 | 20,982,000 | 18,771,000 | 15,238,000 | 14,051,000 | 11,695,000 |
| income from operations | -5,268,000 | 2,904,000 | 4,175,000 | 12,017,000 | 4,606,000 | -4,656,000 | -35,507,000 | -31,739,000 | -8,051,000 | -10,498,000 | -5,420,000 | -9,680,000 | -10,733,000 | -15,248,000 | -12,333,000 | -16,681,000 | -7,474,000 | -45,415,000 | -8,072,000 | -4,066,000 | -11,051,000 | -12,200,000 | -8,197,000 | -1,763,000 | -3,100,000 | -2,067,000 | -3,057,000 | -4,304,000 | -5,917,000 | -8,955,000 | -6,044,000 | -6,368,000 | -6,609,000 | -7,517,000 | -3,672,000 | -4,886,000 | -10,494,000 | |||||||
| yoy | -214.37% | -162.37% | -111.76% | -137.86% | -157.21% | -55.65% | 555.11% | 227.88% | -24.99% | -31.15% | -56.05% | -41.97% | 43.60% | -66.43% | 52.79% | 310.26% | -32.37% | 272.25% | -1.52% | 130.63% | 256.48% | 490.23% | 168.14% | -59.04% | -47.61% | -76.92% | -49.42% | -32.41% | -10.47% | 19.13% | 64.60% | 30.33% | -37.02% | |||||||||||
| qoq | -281.40% | -30.44% | -65.26% | 160.90% | -198.93% | -86.89% | 11.87% | 294.22% | -23.31% | 93.69% | -44.01% | -9.81% | -29.61% | 23.64% | -26.07% | 123.19% | -83.54% | 462.62% | 98.52% | -63.21% | -9.42% | 48.83% | 364.95% | -43.13% | 49.98% | -32.38% | -28.97% | -27.26% | -33.93% | 48.16% | -5.09% | -3.65% | -12.08% | 104.71% | -24.85% | -53.44% | ||||||||
| operating margin % | -4.05% | 2.54% | 3.52% | 10.37% | 4.03% | -4.81% | -36.16% | -35.22% | -8.91% | -12.74% | -6.75% | -12.81% | -14.73% | -22.50% | -18.32% | -27.63% | -13.56% | -123.74% | -23.37% | -13.07% | -53.38% | -39.20% | ||||||||||||||||||||||
| other income | 6,518,000 | 4,524,000 | -732,000 | 4,831,000 | 2,755,000 | 2,748,000 | 5,035,000 | 1,967,000 | -226,000 | 2,407,000 | 1,979,000 | 805,000 | 1,086,000 | 784,000 | 1,016,000 | 1,202,000 | -1,653,000 | -195,000 | 82,000 | -3,000 | 91,000 | 539,000 | 820,000 | 1,091,000 | 841,000 | 453,000 | 488,000 | 333,000 | 150,000 | 226,000 | 123,000 | 134,000 | 119,000 | 100,000 | 75,000 | 48,000 | 36,000 | 43,000 | 35,000 | 28,000 | 32,000 | 19,000 | 12,000 | |
| income before income taxes | 1,250,000 | 7,428,000 | 3,443,000 | 16,848,000 | 7,361,000 | -1,908,000 | -11,535,000 | -29,772,000 | -8,277,000 | -8,091,000 | -8,246,500 | -8,875,000 | -9,647,000 | -14,464,000 | ||||||||||||||||||||||||||||||
| income tax provision | 2,230,000 | 1,627,000 | ||||||||||||||||||||||||||||||||||||||||||
| net income | -980,000 | 7,047,000 | 5,113,000 | 15,155,000 | 5,734,000 | -1,864,000 | -28,293,000 | -29,618,000 | -8,402,000 | -8,091,000 | -3,844,000 | -8,723,000 | -9,532,000 | -14,461,000 | -10,528,000 | -14,129,000 | ||||||||||||||||||||||||||||
| yoy | -117.09% | -478.06% | -118.07% | -151.17% | -168.25% | -76.96% | 636.03% | 239.54% | -11.85% | -44.05% | -63.49% | -38.26% | ||||||||||||||||||||||||||||||||
| qoq | -113.91% | 37.83% | -66.26% | 164.30% | -407.62% | -93.41% | -4.47% | 252.51% | 3.84% | 110.48% | -55.93% | -8.49% | -34.08% | 37.36% | -25.49% | |||||||||||||||||||||||||||||
| net income margin % | -0.75% | 6.16% | 4.31% | 13.08% | 5.01% | -1.92% | -28.81% | -32.87% | -9.30% | -9.82% | -4.79% | -11.54% | -13.08% | -21.33% | -15.64% | -23.40% | 0% | 0% | 0% | 0% | 0% | 0% | ||||||||||||||||||||||
| earnings per share: | ||||||||||||||||||||||||||||||||||||||||||||
| basic | -0.01 | 0.09 | 0.07 | 0.2 | 0.07 | |||||||||||||||||||||||||||||||||||||||
| diluted | -0.01 | 0.09 | 0.06 | 0.19 | 0.07 | |||||||||||||||||||||||||||||||||||||||
| shares used to compute earnings per common share: | ||||||||||||||||||||||||||||||||||||||||||||
| basic | 78,391,502 | 78,028,254 | 377,457 | 77,013,831 | 76,538,325 | |||||||||||||||||||||||||||||||||||||||
| diluted | 78,391,502 | 80,056,024 | 823,320 | 78,464,654 | 77,163,149 | |||||||||||||||||||||||||||||||||||||||
| impairment of long-lived assets | 2,754,000 | 185,000 | 429,000 | 32,039,000 | 34,900,000 | |||||||||||||||||||||||||||||||||||||||
| income tax benefit | 381,000 | -1,670,000 | 1,693,000 | -44,000 | -2,179,000 | -154,000 | 125,000 | 403,000 | -152,000 | -115,000 | -3,000 | -789,000 | -1,350,000 | -152,000 | -3,795,000 | |||||||||||||||||||||||||||||
| intangible asset amortization | 3,653,000 | 4,563,000 | 5,337,000 | 5,341,000 | 5,329,000 | 5,264,000 | 5,213,000 | 5,391,000 | 5,486,000 | 5,474,000 | 4,983,000 | 3,723,000 | 1,801,000 | 1,273,000 | 1,274,000 | 1,273,000 | 1,275,000 | 601,000 | 267,000 | 266,000 | 267,000 | 267,000 | 267,000 | 266,000 | 267,000 | 267,000 | 267,000 | 266,000 | 267,000 | 267,000 | 266,000 | 267,000 | 267,000 | 266,000 | 267,000 | |||||||||
| net income per common share, basic and diluted | -20 | -380 | -410 | -120 | -110 | -50 | -120 | -130 | -200 | -140 | -200 | -130 | -660 | -140 | -80 | -220 | -240 | -160 | -20 | -50 | -50 | -60 | -120 | -180 | -270 | -240 | -210 | -220 | -240 | -120 | -200 | -400 | -360 | -320 | -350 | -340 | -310 | -320 | -6,590 | |||||
| shares used to compute net income per common share, basic and diluted | 74,759,789,000 | 155,886,000 | 72,804,770,000 | 72,478,662,000 | 72,175,457,000 | 93,196,000 | 71,656,694,000 | 71,476,966,000 | 71,229,672,000 | 1,069,674,000 | 69,743,733,000 | 67,316,065,000 | 63,331,702,000 | 1,606,481,000 | 54,858,052,000 | 50,212,123,000 | 49,792,631,000 | 996,675,000 | 48,588,296,000 | 45,586,081,000 | 41,168,593,000 | 1,250,623,000 | 38,620,036,000 | 34,314,234,000 | 34,271,254,000 | 43,912,000 | 33,946,748,000 | 33,873,128,000 | 33,823,889,000 | 965,372,000 | 27,916,819,000 | 27,859,918,000 | 27,817,993,000 | 27,640,806,000 | 26,048,934,000 | 22,539,723,000 | 21,237,196,000 | 21,148,342,000 | 955,890,000 | |||||
| income before income tax benefit | -11,317,000 | -15,479,000 | -9,190,000 | -45,663,000 | ||||||||||||||||||||||||||||||||||||||||
| biopharmaceutical revenue | 1,624,000 | 566,000 | 343,000 | 824,000 | 3,779,000 | 722,000 | ||||||||||||||||||||||||||||||||||||||
| cost of biopharmaceutical revenue | 560,000 | 81,000 | 49,000 | 204,000 | 252,000 | 116,000 | ||||||||||||||||||||||||||||||||||||||
| interest expense | -63,000 | -53,000 | -54,000 | -55,000 | -65,000 | -55,000 | -81,000 | -58,000 | -235,000 | -303,000 | -536,000 | -498,000 | -481,000 | -448,000 | -2,518,000 | -815,000 | -808,000 | -800,000 | -806,000 | -799,000 | -785,000 | |||||||||||||||||||||||
| net income and comprehensive loss | -9,038,000 | -41,868,000 | -8,044,000 | -4,124,000 | -11,025,000 | -11,716,000 | -7,458,000 | -730,000 | -2,494,000 | -1,917,000 | -3,105,000 | -4,469,000 | -6,248,000 | -9,177,000 | -8,439,000 | -7,049,000 | -7,298,000 | -8,217,000 | -4,403,000 | -5,637,000 | -11,243,000 | -10,075,000 | -8,945,000 | -9,136,000 | -7,610,000 | -6,655,000 | -6,674,000 | -6,303,000 | ||||||||||||||||
| collaboration revenue | ||||||||||||||||||||||||||||||||||||||||||||
| revenue | 22,659,500 | 30,973,000 | 30,136,000 | 29,529,000 | 25,750,000 | 23,466,000 | 22,751,000 | 20,041,000 | 19,596,000 | 17,519,000 | 18,406,000 | 16,432,000 | 18,257,000 | 18,603,000 | 14,675,000 | 13,550,000 | 12,335,000 | 11,908,000 | 11,218,000 | 8,677,000 | 7,476,000 | 5,594,000 | ||||||||||||||||||||||
| cost of revenue | 6,601,000 | 9,114,000 | 8,777,000 | 8,513,000 | 8,704,000 | 8,261,000 | 8,246,000 | 7,867,000 | 7,769,000 | 7,169,000 | 6,960,000 | 6,297,000 | 6,515,000 | 6,367,000 | 6,301,000 | 6,279,000 | 5,618,000 | 5,139,000 | 4,566,000 | 3,966,000 | 3,607,000 | 3,132,000 |
We provide you with 20 years income statements for Veracyte stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as earnings, sales and marketing expenses, research and development costs, profits, and profit margins. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Veracyte stock. Explore the full financial landscape of Veracyte stock with our expertly curated income statements.
The information provided in this report about Veracyte stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.